scholarly journals Ischemic Heart Disease Modifies the Association of Atrial Fibrillation With Mortality in Heart Failure With Reduced Ejection Fraction

Author(s):  
Ben N. Mercer ◽  
Aaron Koshy ◽  
Michael Drozd ◽  
Andrew M. N. Walker ◽  
Peysh A. Patel ◽  
...  
2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
C Settergren ◽  
G Savarese ◽  
T Thorvaldsen ◽  
A Meyers ◽  
S Fazeli ◽  
...  

Abstract Background Comorbidities are associated with heart failure (HF) development, severity and outcomes, but may play different roles in HF with preserved (HFpEF) vs. mid-range (HFmrEF) vs. reduced ejection fraction (HFrEF). A detailed characterization of HF patients according to EF and comorbidities may improve prognostication and facilitate trial design. Purpose To investigate characteristics and outcomes in a large and unselected cohort of HF patients according to EF strata and presence/absence of concomitant type 2 diabetes (T2DM), atrial fibrillation (AF) and chronic kidney disease (CKD). Methods Patients enrolled in the Swedish HF registry between 2000–2012 were considered. Kaplan Meier curves and multivariable Cox regression models were fitted to assess risk and predictors of outcomes (HF and all-cause hospitalization; composite of cardiovascular (CV) death and HF hospitalization). Results Of 42,583 patients (23% HFpEF, 21% HFmrEF, 56% HFrEF), 24% had T2DM, 49% CKD defined as eGFR<60 ml/min/1.73m2, and 56% AF. T2DM, AF and CKD coexisted in 8% of the population with similar distribution across all EF strata. AF and CKD were the most likely to coexist. Prevalence of AF and/or CKD was highest in HFpEF and lowest in HFrEF, whereas prevalence of T2DM was similar across the EF spectrum (Figure). Compared to patients without T2DM and/or AF and/or CKD, those with any of them were more likely to suffer from other comorbidities (i.e. hypertension, anemia, COPD), to be inpatients, have more severe HF (higher NYHA class, NT-proBNP levels and use of diuretics, longer HF duration) but less likely to be followed-up in specialty vs. primary care. Concomitant history of ischemic heart disease was more likely in patients with vs. without CKD and/or T2DM but less likely in those with vs without AF. Patients with vs. without T2DM and/or CKD and/or AF had worse prognosis. In particular, risk of HF hospitalization and composite of HF hospitalization/CV death was highest in patients with HFrEF and concomitant comorbidities, whereas the risk of all-cause hospitalization was highest in those with HFpEF or HFmrEF and concomitant comorbidities. Prognostic predictors of CV death/HF hospitalization were consistent in patients with T2DM, CKD or AF, regardless of EF (e.g. male sex, older age, lower EF category, more severe HF, ischemic heart disease, anemia, COPD). Comorbidities burden Conclusion HF patients show a high burden of concomitant diseases, specifically T2DM, CKD and AF. CKD and AF are more prevalent in HFpEF vs. HFmrEF vs. HFrEF, whereas T2DM prevalence is consistent across the EF spectrum. Presence of comorbidities identifies patients with more severe HF regardless of EF category. Presence of comorbidities may identify patients at higher risk of CV outcomes in HFrEF and those at higher risk of non-CV events in HFpEF. Acknowledgement/Funding This study has been supported by funding from Boehringer Ingelheim


2021 ◽  
Vol 16 (7-8) ◽  
pp. 79-86
Author(s):  
O.M. Godlevska ◽  
O.V. Bilchenko ◽  
Ya.Yu. Samburg

In the guidelines of the European Society of Cardiology for heart failure in 2016, the term “heart failure with mid-range ejection fraction” was introduced to refer to the patients with heart failure and a slightly reduced ejection fraction of 40–49 %. Today, it was found that about 20 % of people with heart failure fall into this category. It is proved that ischemic heart disease is one of the leading factors for the formation and progression of diastolic disorders of the left ventricle. More than 90 % of patients with ischemic heart disease have varying degrees of diastolic dysfunction, which may be based on disorders of active relaxation and fibrotic processes in the myocardium, which occur due to progressive atherosclerotic cardiosclerosis or acute myocardial infarction. In this regard, it is important to analyze recent data on the mechanisms involved in the formation of myocardial fibrosis of ischemic origin and its role in the pathogenesis of heart failure. It has been proved that chronic hypoxic ischemic myocardial damage is accompanied by necrosis of cardiomyocytes, in the place of which reparative fibrosis develops, and the collagen fibers that appeared fill the place of cardiomyocytes. Reactive fibrosis (perivascular and interstitial) develops in the border zone between the scar, which is formed due to reparative fibrosis, and the zone of hibernating myocardium, to a lesser extent in the intact myocardium. Its formation is indirectly caused by the pressure overload and overstretching of cardiomyocyte fibers. Myofibroblasts express contractile proteins, similar to smooth muscle actin that provide mechanical tension in the remodeled matrix, thereby reducing the scar area. In any case, the development of fibrosis in the extracellular matrix is an integral part of myocardial remodeling and requires continuing researches aimed at addressing the problem of participation of all mechanisms in the pathogenesis of chronic heart failure on the background of ischemic heart disease depending on its types.


Circulation ◽  
2015 ◽  
Vol 132 (suppl_3) ◽  
Author(s):  
Tetsuari Onishi ◽  
Yasue Tsukishiro ◽  
Hiroya Kawai

Background: Both Left ventricular (LV) global longitudinal strain (GLS) and LV ejection fraction (LVEF) are useful parameters for assessment of LV function. The aim of this study is to confirm the prognostic value of them in patients with non-ischemic and ischemic heart disease. Methods: We studied 179 patients (DCM group: Age 61±15 years, 70 females, LVEF 33±9%) with non-ischemic dilated cardiomyopathy and heart failure symptom, and 97 patients (MI group: Age 66±13 years, 18 females, LVEF 45±7%) who were successfully treated with percutaneous coronary intervention for acute anteroseptal myocardial infarction. Echocardiography was used for LV GLS derived from 2D speckle-tracking method and LVEF with modified Simpson’s method. Outcome was assessed according to death and re-hospitalization with heart failure in the follow-up period. Results: 40 patients in DCM group and 10 patients in MI group experienced at least one event. In these 2 groups, significant differences in GLS and LVEF were found between patients with and without cardiac events (p<0.05). Kaplan-Meier analysis showed patients with worse GLS had an unfavorable outcome in both DCM and MI groups (p<0.05), but LVEF did not associated with outcome. Conclusion: LV GLS has the potential to predict the outcome with higher sensitivity than LVEF in patients with heart disease regardless of ischemic etiology.


Sign in / Sign up

Export Citation Format

Share Document